LeonaBio

LeonaBio FCF/Debt

The Free Cash Flow to Debt Ratio of LeonaBio (LONA) as of Oct 29, 2026 is -5,694.77 %. In the previous year, Free Cash Flow to Debt Ratio was -7,987.10 % — a change of -28.70% (higher).

FCF/Debt

-5,694.77 %

YoY

-28.70%

Last updated:

Free Cash Flow to Debt Ratio of LeonaBio is 2025 -5,694.77 % . Free Cash Flow to Debt Ratio of LeonaBio was 2024 -7,987.10 % . It decreases by -28.70% higher compared to the previous year.

The LeonaBio FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2018
-620.91 USD
Jan 1, 2019
-239.09 USD
Jan 1, 2020
-2,643.30 USD
Jan 1, 2021
-2,326.61 USD
Jan 1, 2022
-3,851.91 USD
Jan 1, 2023
-6,375.84 USD
Jan 1, 2024
-7,987.10 USD
Jan 1, 2025
-5,694.77 USD
The LeonaBio FCF/Debt history
YEARFCF/DebtYoY
-5,694.77 %-28.70%
-7,987.10 %+25.27%
-6,375.84 %+65.52%
-3,851.91 %+65.56%
-2,326.61 %-11.98%
-2,643.30 %+1,005.59%
-239.09 %-61.49%
-620.91 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

LeonaBio Stock analysis

What does LeonaBio do? Athira Pharma, Inc. is a clinical-stage biopharmaceutical company headquartered in Bothell, Washington, that generates revenue by developing small molecules to restore neuronal health and stop neurodegeneration. The firm utilizes its proprietary ATH platform to target and enhance the activity of a vital neuronal growth factor, creating a pipeline of drugs designed to cross the blood brain barrier for the central nervous system or target the peripheral nervous system. This technology underpins the development of ATH-1017, which is specifically intended for the treatment of neurodegenerative disorders with an initial focus on Alzheimer’s disease. The product aims to improve symptoms in cognitively impaired subjects by enhancing neuronal health and promoting regeneration, serving the medical needs of patients suffering from these conditions. LeonaBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about LeonaBio stock

Free Cash Flow to Debt Ratio of LeonaBio is -5,694.77 % in 2025.

Free Cash Flow to Debt Ratio of LeonaBio changed from -7,987.10 % to -5,694.77 %, representing a -28.70% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio LeonaBio since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's LeonaBio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — LeonaBio

All Key Metrics — LeonaBio